Chapter 1: Assessment of lipid status in adults with CKD
========================================================

1.1: **In adults with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (*1C*)**1.2: **In adults with CKD (including those treated with chronic dialysis or kidney transplantation), follow-up measurement of lipid levels is not required for the majority of patients. (*Not Graded*)**

Chapter 2: Pharmacological cholesterol-lowering treatment in adults
===================================================================

2.1.1: **In adults aged ≥50 years with eGFR\<60 ml/min/1.73 m^2^ but not treated with chronic dialysis or kidney transplantation (GFR categories G3a-G5), we recommend treatment with a statin or statin/ezetimibe combination. (*1A*)**2.1.2: **In adults aged ≥50 years with CKD and eGFR≥60 ml/min/1.73 m^2^ (GFR categories G1-G2) we recommend treatment with a statin. (*1B*)**2.2: **In adults aged 18--49 years with CKD but not treated with chronic dialysis or kidney transplantation, we suggest statin treatment in people with one or more of the following (*2A*):** **known coronary disease (myocardial infarction or coronary revascularization)diabetes mellitusprior ischemic strokeestimated 10-year incidence of coronary death or non-fatal myocardial infarction \>10%**

2.3.1: **In adults with dialysis-dependent CKD, we suggest that statins or statin/ezetimibe combination not be initiated. (*2A*)**2.3.2: **In patients already receiving statins or statin/ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (*2C*)**2.4: **In adult kidney transplant recipients, we suggest treatment with a statin. (*2B*)**

Chapter 3: Assessment of lipid status in children with CKD
==========================================================

3.1: **In children with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (*1C*)**3.2: **In children with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest annual follow-up measurement of fasting lipid levels. (*Not Graded*)**

Chapter 4: Pharmacological cholesterol-lowering treatment in children
=====================================================================

4.1: **In children less than 18 years of age with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest that statins or statin/ezetimibe combination not be initiated. (*2C*)**

Chapter 5: Triglyceride-lowering treatment in adults
====================================================

5.1: **In adults with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. (*2D*)**

Chapter 6: Triglyceride-lowering treatment in children
======================================================

6.1: **In children with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. (*2D*)**

**Quick summary of the KDIGO recommendations for lipid-lowering treatment in adults with CKD**
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